Clinical Trials Directory

Trials / Completed

CompletedNCT01518244

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Alcon Research · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

TypeNameDescription
DRUGBrinzolamide/timolol maleate fixed combination

Timeline

Start date
2011-12-01
Primary completion
2013-02-01
Completion
2013-02-01
First posted
2012-01-25
Last updated
2015-08-07
Results posted
2014-04-04

Source: ClinicalTrials.gov record NCT01518244. Inclusion in this directory is not an endorsement.

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Thera (NCT01518244) · Clinical Trials Directory